Madrigal Pharmaceuticals, Inc. MDGL Return on equity

Return on equity at other companies

Eli LillyLLY

102.4%+15.7pp

Gyre Therapeutics, Inc.GYRE

8.2%+4.2pp

AltimmuneALT

-42.7%-8.7pp

Viking TherapeuticsVKTX

-70%-94.5pp

Wave Life SciencesWVE

-68.3%—

Arrowhead ResearchARWR

-46.4%+341pp

FAQ

What is Madrigal Pharmaceuticals, Inc.'s return on equity?

Madrigal Pharmaceuticals, Inc. (MDGL) reported return on equity of -53.3% in Q2 2026.

How has Madrigal Pharmaceuticals, Inc.'s return on equity changed year-over-year?

Madrigal Pharmaceuticals, Inc.'s return on equity decreased by 46.8% year-over-year, from -36.3% to -53.3%.

What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s return on equity?

Over 5 years (2020 to 2025), Madrigal Pharmaceuticals, Inc.'s return on equity has grown at a -7.2% compound annual growth rate (CAGR), from -61.6% to -42.5%.

What does return on equity mean?

Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.